{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:13:22Z","timestamp":1788783202584,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":81,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-57828-0","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:33:51Z","timestamp":1781778831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["LINC00222 regulates FOXO3 to interfere with \u03b2-catenin signaling pathway and suppresses prostate cancer progression"],"prefix":"10.1038","volume":"16","author":[{"given":"Hui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyou","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiameng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuoqi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"57828_CR1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.4111\/icu.20240229","volume":"65","author":"K 1 Am","year":"2024","unstructured":"1 Am, K., Rajan, S., Alkhamees, P., Holley, M., Lakshmanan, V. K. & M. & Prostate cancer theragnostics biomarkers: An update. Investig Clin. Urol. 65, 527\u2013539. https:\/\/doi.org\/10.4111\/icu.20240229 (2024).","journal-title":"Investig Clin. Urol."},{"key":"57828_CR2","doi-asserted-by":"publisher","first-page":"153303382412900","DOI":"10.1177\/15330338241290029","volume":"23","author":"P 2 Agbetuyi-Tayo","year":"2024","unstructured":"2 Agbetuyi-Tayo, P., Gbadebo, M., Rotimi, O. A. & Rotimi, S. O. Advancements in Biomarkers of Prostate Cancer: A Review. Technol. Cancer Res. Treat. 23, 15330338241290029. https:\/\/doi.org\/10.1177\/15330338241290029 (2024).","journal-title":"Technol. Cancer Res. Treat."},{"key":"57828_CR3","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","volume":"333","author":"R 3 Raychaudhuri","year":"2025","unstructured":"3 Raychaudhuri, R., Lin, D. W. & Montgomery, R. B. Prostate Cancer: A Review. JAMA 333, 1433\u20131446. https:\/\/doi.org\/10.1001\/jama.2025.0228 (2025).","journal-title":"JAMA"},{"key":"57828_CR4","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1038\/s41416-024-02854-w","volume":"131","author":"M 4 Shen","year":"2024","unstructured":"4 Shen, M. et al. Identification of a 5-gene signature panel for the prediction of prostate cancer progression. Br. J. Cancer. 131, 1748\u20131761. https:\/\/doi.org\/10.1038\/s41416-024-02854-w (2024).","journal-title":"Br. J. Cancer"},{"key":"57828_CR5","first-page":"682","volume":"9","author":"P 5 Luo","year":"2019","unstructured":"5 Luo, P. et al. The human positive cofactor 4 promotes androgen-independent prostate cancer development and progression through HIF-1\u03b1\/\u03b2-catenin pathway. Am. J. Cancer Res. 9, 682\u2013698 (2019).","journal-title":"Am. J. Cancer Res."},{"key":"57828_CR6","doi-asserted-by":"publisher","unstructured":"Lv, S. et al. 6 Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer. J Clin Invest 131, (2021). https:\/\/doi.org\/10.1172\/jci141335","DOI":"10.1172\/jci141335"},{"key":"57828_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/pcan.2017.2","volume":"20","author":"MK 7 Siu","year":"2017","unstructured":"7 Siu, M. K. et al. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer. Prostate Cancer Prostatic Dis. 20, 172\u2013178. https:\/\/doi.org\/10.1038\/pcan.2017.2 (2017).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"57828_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL 8 Siegel","year":"2024","unstructured":"8 Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349. https:\/\/doi.org\/10.3322\/caac.21820 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"57828_CR9","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/jnci\/djac066","volume":"114","author":"LD 9 Borregales","year":"2022","unstructured":"9 Borregales, L. D. et al. Grade Migration of Prostate Cancer in the United States During the Last Decade. J. Natl. Cancer Inst. 114, 1012\u20131019. https:\/\/doi.org\/10.1093\/jnci\/djac066 (2022).","journal-title":"J. Natl. Cancer Inst."},{"key":"57828_CR10","doi-asserted-by":"publisher","first-page":"1124111","DOI":"10.3389\/fendo.2023.1124111","volume":"14","author":"DS 10 Souza","year":"2023","unstructured":"10 Souza, D. S., Macheroni, C., Pereira, G. J. S., Vicente, C. M. & Porto, C. S. Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor. Front. Endocrinol. (Lausanne). 14, 1124111. https:\/\/doi.org\/10.3389\/fendo.2023.1124111 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"57828_CR11","doi-asserted-by":"publisher","unstructured":"Lima, T. et al. 11 Gal-3 Protein Expression and Localization in Prostate Tumours. Curr Oncol 30, 2729\u20132742, (2023). https:\/\/doi.org\/10.3390\/curroncol30030206","DOI":"10.3390\/curroncol30030206"},{"key":"57828_CR12","doi-asserted-by":"publisher","first-page":"e753","DOI":"10.1038\/cddis.2013.277","volume":"4","author":"Y 12 Wang","year":"2013","unstructured":"12 Wang, Y. et al. The significance of galectin-3 as a new basal cell marker in prostate cancer. Cell. Death Dis. 4, e753. https:\/\/doi.org\/10.1038\/cddis.2013.277 (2013).","journal-title":"Cell. Death Dis."},{"key":"57828_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.21873\/anticanres.11297","volume":"37","author":"TO 13 Dondoo","year":"2017","unstructured":"13 Dondoo, T. O. et al. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer. Anticancer Res. 37, 125\u2013134. https:\/\/doi.org\/10.21873\/anticanres.11297 (2017).","journal-title":"Anticancer Res."},{"key":"57828_CR14","doi-asserted-by":"publisher","unstructured":"14 Sharma, S. et al. Use of Glycoproteins-Prostate-Specific Membrane Antigen and Galectin-3 as Primary Tumor Markers and Therapeutic Targets in the Management of Metastatic Prostate Cancer. Cancers (Basel). 14. https:\/\/doi.org\/10.3390\/cancers14112704 (2022).","DOI":"10.3390\/cancers14112704"},{"key":"57828_CR15","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.3389\/fimmu.2020.01820","volume":"11","author":"S 15 Caputo","year":"2020","unstructured":"15 Caputo, S. et al. Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis. Front. Immunol. 11, 1820. https:\/\/doi.org\/10.3389\/fimmu.2020.01820 (2020).","journal-title":"Front. Immunol."},{"key":"57828_CR16","doi-asserted-by":"publisher","first-page":"e1434467","DOI":"10.1080\/2162402x.2018.1434467","volume":"7","author":"M 16 Farhad","year":"2018","unstructured":"16 Farhad, M., Rolig, A. S. & Redmond, W. L. The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. Oncoimmunology 7, e1434467. https:\/\/doi.org\/10.1080\/2162402x.2018.1434467 (2018).","journal-title":"Oncoimmunology"},{"key":"57828_CR17","doi-asserted-by":"publisher","unstructured":"17 Tiraboschi, C. et al. Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome. J. Immunother Cancer. 8 https:\/\/doi.org\/10.1136\/jitc-2020-001535 (2020).","DOI":"10.1136\/jitc-2020-001535"},{"key":"57828_CR18","doi-asserted-by":"publisher","unstructured":"18, Habrowska-G\u00f3rczy\u0144ska, D. E., Kozie\u0142, M. J., Kowalska, K. & Piastowska-Ciesielska A. W. FOXO3a and Its Regulators in Prostate Cancer. Int. J. Mol. Sci. 22 https:\/\/doi.org\/10.3390\/ijms222212530 (2021).","DOI":"10.3390\/ijms222212530"},{"key":"57828_CR19","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/acel.12625","volume":"16","author":"TA 19 Donlon","year":"2017","unstructured":"19 Donlon, T. A. et al. FOXO3 longevity interactome on chromosome 6. Aging Cell. 16, 1016\u20131025. https:\/\/doi.org\/10.1111\/acel.12625 (2017).","journal-title":"Aging Cell."},{"key":"57828_CR20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10555-020-09883-w","volume":"39","author":"Y 20 Jiramongkol","year":"2020","unstructured":"20 Jiramongkol, Y. & Lam, E. W. FOXO transcription factor family in cancer and metastasis. Cancer Metastasis Rev. 39, 681\u2013709. https:\/\/doi.org\/10.1007\/s10555-020-09883-w (2020).","journal-title":"Cancer Metastasis Rev."},{"key":"57828_CR21","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. 21 Critical role of FOXO3a in carcinogenesis. Mol Cancer 17, 104, (2018). https:\/\/doi.org\/10.1186\/s12943-018-0856-3","DOI":"10.1186\/s12943-018-0856-3"},{"key":"57828_CR22","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.tips.2022.09.010","volume":"43","author":"22","year":"2022","unstructured":"22 et al. FOXO transcription factors as therapeutic targets in human diseases. Trends Pharmacol. Sci. 43, 1070\u20131084. https:\/\/doi.org\/10.1016\/j.tips.2022.09.010 (2022).","journal-title":"Trends Pharmacol. Sci."},{"key":"57828_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.canlet.2019.10.006","volume":"468","author":"Z 23 Shen","year":"2020","unstructured":"23 Shen, Z., Zhou, L., Zhang, C. & Xu, J. Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel. Cancer Lett. 468, 88\u2013101. https:\/\/doi.org\/10.1016\/j.canlet.2019.10.006 (2020).","journal-title":"Cancer Lett."},{"key":"57828_CR24","first-page":"15246","volume":"8","author":"Z 24 Lv","year":"2015","unstructured":"24 Lv, Z., Rao, P. & Li, W. MiR-592 represses FOXO3 expression and promotes the proliferation of prostate cancer cells. Int. J. Clin. Exp. Med. 8, 15246\u201315253 (2015).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"57828_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.yexcr.2018.01.036","volume":"364","author":"R 25 Li","year":"2018","unstructured":"25 Li, R., Quan, Y. & Xia, W. SIRT3 inhibits prostate cancer metastasis through regulation of FOXO3A by suppressing Wnt\/\u03b2-catenin pathway. Exp. Cell. Res. 364, 143\u2013151. https:\/\/doi.org\/10.1016\/j.yexcr.2018.01.036 (2018).","journal-title":"Exp. Cell. Res."},{"key":"57828_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1158\/1541-7786.MCR-04-0163","volume":"3","author":"RL 26 Lynch","year":"2005","unstructured":"26 Lynch, R. L. et al. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Mol. Cancer Res. 3, 163\u2013169. https:\/\/doi.org\/10.1158\/1541-7786.MCR-04-0163 (2005).","journal-title":"Mol. Cancer Res."},{"key":"57828_CR27","doi-asserted-by":"publisher","first-page":"119798","DOI":"10.1016\/j.lfs.2021.119798","volume":"282","author":"K 27 Zhou","year":"2021","unstructured":"27 Zhou, K., Wei, Y., Li, X. & Yang, X. MiR-223-3p targets FOXO3a to inhibit radiosensitivity in prostate cancer by activating glycolysis. Life Sci. 282, 119798. https:\/\/doi.org\/10.1016\/j.lfs.2021.119798 (2021).","journal-title":"Life Sci."},{"key":"57828_CR28","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/jmedgenet-2015-103334","volume":"52","author":"X 28 Qi","year":"2015","unstructured":"28 Qi, X. et al. ceRNA in cancer: possible functions and clinical implications. J. Med. Genet. 52, 710\u2013718. https:\/\/doi.org\/10.1136\/jmedgenet-2015-103334 (2015).","journal-title":"J. Med. Genet."},{"key":"57828_CR29","doi-asserted-by":"publisher","unstructured":"29 Taheri, M., Safarzadeh, A., Hussen, B. M., Ghafouri-Fard, S. & Baniahmad, A. LncRNA\/miRNA\/mRNA Network Introduces Novel Biomarkers in Prostate Cancer. Cells 11 https:\/\/doi.org\/10.3390\/cells11233776 (2022).","DOI":"10.3390\/cells11233776"},{"key":"57828_CR30","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00404-022-06423-5","volume":"306","author":"A 30 Shetty","year":"2022","unstructured":"30 Shetty, A., Venkatesh, T., Kabbekodu, S. P., Tsutsumi, R. & Suresh, P. S. LncRNA-miRNA-mRNA regulatory axes in endometrial cancer: a comprehensive overview. Arch. Gynecol. Obstet. 306, 1431\u20131447. https:\/\/doi.org\/10.1007\/s00404-022-06423-5 (2022).","journal-title":"Arch. Gynecol. Obstet."},{"key":"57828_CR31","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1186\/s12885-019-5983-8","volume":"19","author":"RS 31 Zhou","year":"2019","unstructured":"31 Zhou, R. S. et al. Integrated analysis of lncRNA-miRNA-mRNA ceRNA network in squamous cell carcinoma of tongue. BMC Cancer. 19, 779. https:\/\/doi.org\/10.1186\/s12885-019-5983-8 (2019).","journal-title":"BMC Cancer"},{"key":"57828_CR32","doi-asserted-by":"publisher","first-page":"8312","DOI":"10.1111\/jcmm.16784","volume":"25","author":"C 32 Bi","year":"2021","unstructured":"32 Bi, C. & Wang, G. LINC00472 suppressed by ZEB1 regulates the miR-23a-3p\/FOXO3\/BID axis to inhibit the progression of pancreatic cancer. J. Cell. Mol. Med. 25, 8312\u20138328. https:\/\/doi.org\/10.1111\/jcmm.16784 (2021).","journal-title":"J. Cell. Mol. Med."},{"key":"57828_CR33","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/iub.1699","volume":"70","author":"Y 33 Zhou","year":"2018","unstructured":"33 Zhou, Y. et al. LncRNA UCA1 impacts cell proliferation, invasion, and migration of pancreatic cancer through regulating miR-96\/FOXO3. IUBMB Life. 70, 276\u2013290. https:\/\/doi.org\/10.1002\/iub.1699 (2018).","journal-title":"IUBMB Life"},{"key":"57828_CR34","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.3892\/or.2018.6584","volume":"40","author":"K 34 Cheng","year":"2018","unstructured":"34 Cheng, K., Zhao, Z., Wang, G., Wang, J. & Zhu, W. lncRNA GAS5 inhibits colorectal cancer cell proliferation via the miR\u2013182\u20135p\/FOXO3a axis. Oncol. Rep. 40, 2371\u20132380. https:\/\/doi.org\/10.3892\/or.2018.6584 (2018).","journal-title":"Oncol. Rep."},{"key":"57828_CR35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","volume":"13","author":"Y 35 Zhang","year":"2020","unstructured":"35 Zhang, Y. & Wang, X. Targeting the Wnt\/beta-catenin signaling pathway in cancer. J. Hematol. Oncol. 13, 165. https:\/\/doi.org\/10.1186\/s13045-020-00990-3 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"57828_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12032-023-02254-9","volume":"41","author":"YM 36 Liu","year":"2023","unstructured":"36 Liu, Y. M. et al. Gastrodin inhibits prostate cancer proliferation by targeting canonical Wnt\/beta-catenin signaling pathway. Med. Oncol. 41, 32. https:\/\/doi.org\/10.1007\/s12032-023-02254-9 (2023).","journal-title":"Med. Oncol."},{"key":"57828_CR37","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.cellsig.2015.01.001","volume":"27","author":"H 37 Liu","year":"2015","unstructured":"37 Liu, H. et al. FOXO3a modulates WNT\/beta-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells. Cell. Signal. 27, 510\u2013518. https:\/\/doi.org\/10.1016\/j.cellsig.2015.01.001 (2015).","journal-title":"Cell. Signal."},{"key":"57828_CR38","doi-asserted-by":"publisher","unstructured":"38 Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402\u2013408, (2001). https:\/\/doi.org\/10.1006\/meth.2001.1262","DOI":"10.1006\/meth.2001.1262"},{"key":"57828_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/his.13472","volume":"73","author":"M 39 Varma","year":"2018","unstructured":"39 Varma, M., Berney, D., Oxley, J. & Trpkov, K. Gleason score assignment is the sole responsibility of the pathologist. Histopathology 73, 5\u20137. https:\/\/doi.org\/10.1111\/his.13472 (2018).","journal-title":"Histopathology"},{"key":"57828_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12032-023-02251-y","volume":"41","author":"AZ 40 Touchaei","year":"2023","unstructured":"40 Touchaei, A. Z., Vahidi, S. & Samadani, A. A. Decoding the interaction between miR-19a and CBX7 focusing on the implications for tumor suppression in cancer therapy. Med. Oncol. 41, 21. https:\/\/doi.org\/10.1007\/s12032-023-02251-y (2023).","journal-title":"Med. Oncol."},{"key":"57828_CR41","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1177\/1535370217708198","volume":"242","author":"M 41 Yan","year":"2017","unstructured":"41 Yan, M., Li, G. & An, J. Discovery of small molecule inhibitors of the Wnt\/\u03b2-catenin signaling pathway by targeting \u03b2-catenin\/Tcf4 interactions. Exp. Biol. Med. (Maywood). 242, 1185\u20131197. https:\/\/doi.org\/10.1177\/1535370217708198 (2017).","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"57828_CR42","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1158\/0008-5472.Can-17-2683","volume":"78","author":"L 42 Liu","year":"2018","unstructured":"42 Liu, L. et al. RNF6 Promotes Colorectal Cancer by Activating the Wnt\/\u03b2-Catenin Pathway via Ubiquitination of TLE3. Cancer Res. 78, 1958\u20131971. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-2683 (2018).","journal-title":"Cancer Res."},{"key":"57828_CR43","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(22)00035-3","volume":"10","author":"M 43 Pizzato","year":"2022","unstructured":"43 Pizzato, M. et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 10, 264\u2013272. https:\/\/doi.org\/10.1016\/S2213-8587(22)00035-3 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"57828_CR44","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo, M. Y., Rathkopf, D. E. & Kantoff, P. Treatment of Advanced Prostate Cancer. Annu. Rev. Med. 70, 479\u2013499. https:\/\/doi.org\/10.1146\/annurev-med-051517-011947 (2019).","journal-title":"Annu. Rev. Med."},{"key":"57828_CR45","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.semcancer.2017.11.007","volume":"50","author":"T 45 Hou","year":"2018","unstructured":"45 Hou, T., Li, Z., Zhao, Y. & Zhu, W. G. Mechanisms controlling the anti-neoplastic functions of FoxO proteins. Semin Cancer Biol. 50, 101\u2013114. https:\/\/doi.org\/10.1016\/j.semcancer.2017.11.007 (2018).","journal-title":"Semin Cancer Biol."},{"key":"57828_CR46","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1038\/s41388-021-01757-x","volume":"40","author":"T 46 Tsuji","year":"2021","unstructured":"46 Tsuji, T. et al. FOXO3 is a latent tumor suppressor for FOXO3-positive and cytoplasmic-type gastric cancer cells. Oncogene 40, 3072\u20133086. https:\/\/doi.org\/10.1038\/s41388-021-01757-x (2021).","journal-title":"Oncogene"},{"key":"57828_CR47","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.biopha.2018.06.165","volume":"106","author":"H 47 Zhang","year":"2018","unstructured":"47 Zhang, H., Wang, Y., Lu, J. & Zhao, Y. Long non-coding RNA LINC00222 regulates GSK3beta activity and promotes cell apoptosis in lung adenocarcinoma. Biomed. Pharmacother. 106, 755\u2013762. https:\/\/doi.org\/10.1016\/j.biopha.2018.06.165 (2018).","journal-title":"Biomed. Pharmacother"},{"key":"57828_CR48","doi-asserted-by":"publisher","unstructured":"48 Hill, M. & Tran, N. miRNA interplay: mechanisms and consequences in cancer. Dis. Model. Mech. 14 https:\/\/doi.org\/10.1242\/dmm.047662 (2021).","DOI":"10.1242\/dmm.047662"},{"key":"57828_CR49","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.7150\/ijbs.47203","volume":"16","author":"B 49 He","year":"2020","unstructured":"49 He, B. et al. miRNA-based biomarkers, therapies, and resistance in Cancer. Int. J. Biol. Sci. 16, 2628\u20132647. https:\/\/doi.org\/10.7150\/ijbs.47203 (2020).","journal-title":"Int. J. Biol. Sci."},{"key":"57828_CR50","doi-asserted-by":"publisher","unstructured":"50 Fan, H. et al. MiR-19a suppresses ferroptosis of colorectal cancer cells by targeting IREB2. Bioengineered 13, 12021\u201312029, (2022). https:\/\/doi.org\/10.1080\/21655979.2022.2054194","DOI":"10.1080\/21655979.2022.2054194"},{"key":"57828_CR51","doi-asserted-by":"publisher","unstructured":"51 Peng, Y., Huang, D., Ma, K., Deng, X. & Shao, Z. MiR-19a as a prognostic indicator for cancer patients: a meta-analysis. Biosci. Rep. 39 https:\/\/doi.org\/10.1042\/BSR20182370 (2019).","DOI":"10.1042\/BSR20182370"},{"key":"57828_CR52","first-page":"2028","volume":"25","author":"Y 52 Wang","year":"2020","unstructured":"52 Wang, Y., Hu, J., Qi, G., Wang, S. & Gao, J. miR-19a promotes the metastasis and EMT through CUL5 in prostate cancer cell line PC3. J. BUON. 25, 2028\u20132035 (2020).","journal-title":"J. BUON"},{"key":"57828_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ctrv.2017.11.002","volume":"62","author":"N 53 Krishnamurthy","year":"2018","unstructured":"53 Krishnamurthy, N. & Kurzrock, R. Targeting the Wnt\/beta-catenin pathway in cancer: Update on effectors and inhibitors. Cancer Treat. Rev. 62, 50\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2017.11.002 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"57828_CR54","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-025-02363-1","volume":"24","author":"X 54 Wu","year":"2025","unstructured":"54 Wu, X., Que, H., Li, Q. & Wei, X. Wnt\/\u03b2-catenin mediated signaling pathways in cancer: recent advances, and applications in cancer therapy. Mol. Cancer. 24, 171. https:\/\/doi.org\/10.1186\/s12943-025-02363-1 (2025).","journal-title":"Mol. Cancer"},{"key":"57828_CR55","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41419-022-05200-1","volume":"13","author":"H 55 Yao","year":"2022","unstructured":"55 Yao, H. et al. KCTD9 inhibits the Wnt\/\u03b2-catenin pathway by decreasing the level of \u03b2-catenin in colorectal cancer. Cell. Death Dis. 13, 761. https:\/\/doi.org\/10.1038\/s41419-022-05200-1 (2022).","journal-title":"Cell. Death Dis."},{"key":"57828_CR56","doi-asserted-by":"publisher","first-page":"2251696","DOI":"10.1080\/21655979.2023.2251696","volume":"14","author":"A Dev Jr","year":"2023","unstructured":"Dev, A. Jr, Vachher, M., Prasad, C. & 56, & P. \u03b2-catenin inhibitors in cancer therapeutics: intricacies and way forward. Bioengineered 14, 2251696. https:\/\/doi.org\/10.1080\/21655979.2023.2251696 (2023).","journal-title":"Bioengineered"},{"key":"57828_CR57","doi-asserted-by":"publisher","first-page":"9085","DOI":"10.1007\/s00432-023-04829-5","volume":"149","author":"A 57 Samy","year":"2023","unstructured":"57 Samy, A., Hussein, M. A. & Munirathinam, G. Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the beta-catenin signaling pathway. J. Cancer Res. Clin. Oncol. 149, 9085\u20139104. https:\/\/doi.org\/10.1007\/s00432-023-04829-5 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"57828_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4419-1145-2_1","volume":"656","author":"J 58 Kennell","year":"2009","unstructured":"58 Kennell, J. & Cadigan, K. M. APC and beta-catenin degradation. Adv. Exp. Med. Biol. 656, 1\u201312. https:\/\/doi.org\/10.1007\/978-1-4419-1145-2_1 (2009).","journal-title":"Adv. Exp. Med. Biol."},{"key":"57828_CR59","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/ejhg.2012.281","volume":"21","author":"Y 59 Chen","year":"2013","unstructured":"59 Chen, Y. et al. APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis. Eur. J. Hum. Genet. 21, 929\u2013935. https:\/\/doi.org\/10.1038\/ejhg.2012.281 (2013).","journal-title":"Eur. J. Hum. Genet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57828-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57828-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57828-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:05:01Z","timestamp":1788782701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57828-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["57828"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-57828-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Ethics Committee of Peking University International Hospital (Approval no. 2022-KY-0070-01).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27887"}}